Articles of Annual Meeting of Japanese Association of Cardiovascular Pharmacology | Volume 31, Issue / 2021

Search by Journal

HOME
> Search by Journal
> Annual Meeting of Japanese Association of Cardiovascular Pharmacology

Annual Meeting of Japanese Association of Cardiovascular Pharmacology

Volume 31, Issue / 2021

English Article

Japanese Article

Please note that metadata of J-type articlesare generated by machine-translation and the original texts are written in Japanese.

	In the 31st Japan circulation Japanese Pharmacological Society academic meeting holding 中田徹男 Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 1-1, 2021.

	Mitochondrial energy metabolism and quality control aiming at cardiac long-term function maintenance 的場聖明 Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 18-18, 2021.

	S-01. Pathophysiological significance of the natriuresis peptide in the cardiovascular illness 中川靖章1), 柳澤洋1), 錦見俊雄1)2), 桑原宏一郎3), 八十田明宏4), 中尾一和5), 木村剛1) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 20-20, 2021.

	S-02. Mitochondrial quality control and drug discovery application by the automatic fuzzy 星野温 Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 22-23, 2021.

	S-03. It is a treatment strategy of the heart failure after ischemia that paid its attention to active sulfur molecules 西田基宏1)2), 西村明幸2), 田中智弘2), 加藤百合1), 西山和宏1) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 24-24, 2021.

	About history and the structure of the Shinto shrine 西野武志 Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 26-26, 2021.

	O-01. Improvement effect of SGLT2 inhibitor Luseogliflozin for the left ventricular dilatation dysfunction of the diabetic cardiomyopathy early stage 三上義礼1), 伊藤雅方1), 大島大輔1), 窪田哲也2), 冨田太一郎1), 諸井雅男2), 赤羽悟美1) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 30-30, 2021.

	O-02. The sarpogrelate which was a serotonin 2A receptor selective blocker inhibited extension of the heart failure by inhibiting ERK1/2-GATA4 course 清水果奈1)2), 船本雅文1)2), 砂川陽一1)2)3), 村井範行1), 刀坂泰史1)2)3), 清水聡史1)2), 長谷川浩二1)2), 森本達也1)2)3) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 31-31, 2021.

	O-03. Effect on cardiotoxicity examination of the doxorubicin with the wogonin of the compound derived from a crude drug 船本雅文, 池田康将 Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 32-32, 2021.

	O-04. Effect of the Pdcd1 overexpression on doxorubicin-induced apoptosis in cardiac muscle cells and the cancer cell 菅野秀一, 蓬田伸, 原明義 Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 33-33, 2021.

	O-05. YAP aggravates the glycolysis system of cardiac muscle cells through Tead1 and Hif-1α 柏原俊英1), 中原努1), 佐渡島純一2) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 34-34, 2021.

	O-06. Effect of the GLP-1 receptor agonist on hyperglycosemia disorder in the culture glomerulus epicyte 宮石和恭, 小原幸, 小西巧真, 鈴木佑実, 宮川真由香, 鳥羽裕恵, 中田徹男 Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 35-35, 2021.

	O-07. We cause a nephrosis-like symptom, and the expression of transcription factor OASIS rise in the podocyte leads to the constancy rupture of the kidney 尾花理徳1)2)3)4), 三宅芳明1), 山本彩葉1), 田中翔大1), 前田真貴子5), 岡田欣晃1), 今泉和則6), 淺沼克彦7), 藤尾慈1)2) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 36-36, 2021.

	O-08. Participation of the indoxyl sulfate in the vascular endothelium dysfunction to be complicated for ischemic acute renal failure 中川恵輔1), 堂内政秀1), 神田将哉1), 鎌田沙彩1), 小渕修平2), 田中亮輔1), 田和正志1), 松村靖夫1), 大喜多守1) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 37-37, 2021.

	O-09. Anemia disrupts renal compensatory growth without paralysis of growth signaling pathway 中野大介, Zhang Anqi, Guan Yu, 西山成 Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 38-38, 2021.

	O-10. Anemia disrupts kidney vicarious hypertrophy mechanism and causes an easy fibrosis state 中野大介, 西山成 Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 39-39, 2021.

	O-11. The high blood pressure that was found in 3-mercaptopyruvic acid sulfur transferase (3MST) loss mouse 筒井正人1), 戸塚裕一1)2), 伊波幸紀1), 比嘉章太郎1)2), 坂梨まゆ子1)3), 山下弘高1), 稲福斉2), 国吉幸男2), 古川浩二郎2) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 40-40, 2021.

	O-12. Effect on arteriosclerosis progress of CCR4-NOT through the macrophage 安健博, 山口智和, 星崎みどり, 久場敬司 Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 41-41, 2021.

	O-13. Indoxyl sulfate makes the endothelin-1-induced shrinkage increase by the NO/cGMP signal failure in the rat thoracic aorta 松本貴之, 小澤恵介, 新谷涼葉, 垣花志帆, 加藤麻衣, 佐藤悠太, 田中佑奈, 下山瑠惟, 永井瀬名, 山田愛子, 田口久美子, 小林恒雄 Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 42-42, 2021.

	O-14. Pharmacologic elucidation of a blood vessel physiological function of thrombin and the molecular mechanism 岡村昌宏1), 三明淳一朗2), 友森匠也1), 澤野達哉2), 高見亜衣子1), Kurniawan Priyo Agung2), 小倉一能1), 加藤克1), 川谷俊輔1), 長田佳子2), 山本一博1), 今村武史2) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 43-43, 2021.

O-14. Pharmacologic elucidation of a blood vessel physiological function of thrombin and the molecular mechanism
岡村昌宏1), 三明淳一朗2), 友森匠也1), 澤野達哉2), 高見亜衣子1), Kurniawan Priyo Agung2), 小倉一能1), 加藤克1), 川谷俊輔1), 長田佳子2), 山本一博1), 今村武史2)
Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 43-43, 2021.

	O-15. Transcription factor NR4A1 inhibits vascular smooth muscle cell death by the extension load 趙晶, 中平毅一, 京谷陽司, 吉栖正典 Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 44-44, 2021.

	O-16. Efficacy examination of the new non-steroid type MR blocker for the hypertensive merger heart failure rat 西山成1), 澤野達哉2), 中野大介1), 北田研人1), 今村武史2), ラフマンアサダ1) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 45-45, 2021.

	O-17. We identified a candidate compound of new heart failure treatment to inhibit cardiac muscle cells enlargement by High Throughput Screening 片桐宇大1), 山田美帆1), 清水聡史1)3), 砂川陽一1)3)4), 船本雅文1)3), 清水果奈1)3), 刀坂泰史1)3)4), 小郷尚久2), 浅井章良2), 長谷川浩二1)3), 森本達也1)3)4) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 46-46, 2021.

O-17. We identified a candidate compound of new heart failure treatment to inhibit cardiac muscle cells enlargement by High Throughput Screening
片桐宇大1), 山田美帆1), 清水聡史1)3), 砂川陽一1)3)4), 船本雅文1)3), 清水果奈1)3), 刀坂泰史1)3)4), 小郷尚久2), 浅井章良2), 長谷川浩二1)3), 森本達也1)3)4)
Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 46-46, 2021.

	O-18. Creation of the childhood heart failure therapy using new menstruation properties of the AT1 angiotensin receptor 川岸裕幸1)2), 冨田(沼賀)拓郎2), 中田勉3), 松岡大輔4), 山田充彦2) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 47-47, 2021.

	O-19. Examination of the pharmacologic action of PRMT5 selective inhibitor EPZ015666 for heart fibrosis 刀坂泰史1)2)3), 村田謄行1), 矢部晴海1), 砂川陽一1)2)3), 清水聡史1), 清水果奈1), 長谷川浩二1)2), 森本達也1)2)3) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 48-48, 2021.

	O-20. Mechanism of the protection for ischemic/reperfusion inductivity ventricular arrythmia of Canstatin 岡田宗善1), 杉山彰1)2), 田場千尋1), 塩田友里恵1), 大谷紘資1), 山脇英之1) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 49-49, 2021.

	O-21. Improvement of the COVID-19 acute pulmonary injury by the angiotensin-converting enzyme 2 (ACE2) enzyme activity 山口智和1), 星崎みどり1)2), 湊隆文1), 韮澤悟3), 浅賀正充4), 新山真由美5), 安健博1), 永田諭志6), 鎌田春彦5), 神谷亘7), 河岡義裕8), 保富康宏4), 今井由美子2), 久場敬司1) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 50-50, 2021.

O-21. Improvement of the COVID-19 acute pulmonary injury by the angiotensin-converting enzyme 2 (ACE2) enzyme activity
山口智和1), 星崎みどり1)2), 湊隆文1), 韮澤悟3), 浅賀正充4), 新山真由美5), 安健博1), 永田諭志6), 鎌田春彦5), 神谷亘7), 河岡義裕8), 保富康宏4), 今井由美子2), 久場敬司1)
Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 50-50, 2021.

	O-22. Tissue sodium, water retention produces the hepatocytes cancer rat by body fluid maintenance through aldosterone supersecretion and the urea 北田研人, 木戸口慧, 中野大介, 西山成 Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 51-51, 2021.

	O-23. NRDC regulates sinus automaticity through transcriptional regulation of ion channels 大野美紀子1), 松浦博2), 牧山武3), 糀谷泰彦3), 西清人1), 松田真太郎3), 木村剛3), 西英一郎1) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 52-52, 2021.

	O-24. Analysis of the effect that sympathetic denervation gives for the neonates heart development 冨田拓郎1), 川岸裕幸1), 中田勉2), 山田充彦1) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 53-53, 2021.

	YD-01. In the pressure load heart failure model mouse, Compound A which was a ginger extract inhibited extension of the heart failure 川瀬裕斗1), 清水果奈1)2), 船本雅史1)2), 砂川陽一1)2)3), 刀坂泰史1)2)3), 清水聡史1)2), 長谷川浩二1)2), 森本達也1)2)3) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 56-56, 2021.

	YD-02. The endogenous YAP activity in culture cardiac muscle cells reinforces the increase instruction effect with the GSK3 inhibitor 亀谷祐介1), 田中翔大1), 鈴木翔大1), 梅田綾香1), 前田真貴子2), 岡田欣晃1), 尾花理徳1), 藤尾慈1) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 57-57, 2021.

	YD-03. The homodimeric formation inhibition of transcription factor GATA4 inhibits cardiac muscle cells enlargement response 清水聡史1)2), 砂川陽一1)2)3), 刀坂泰史1)2)3), 船本雅文1)2), 清水果奈1)2), Nurmila Sari1), 長谷川浩二1)2), 森本達也1)2)3) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 58-58, 2021.

	YD-04. A preventive preparation search for the cisplatin-induced renal failure using the large-scale medical information and inspection of the effectiveness 神田将哉1)2), 合田光寛1)2), 吉岡俊彦1)2), 吉田愛美1), 新村貴博2), 相澤風花2), 八木健太3), 濱野裕章3), 中馬真幸4), 岡田直人2), 石澤有紀5), 座間味義人1)6), 石澤啓介1)2) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 59-59, 2021.

YD-04. A preventive preparation search for the cisplatin-induced renal failure using the large-scale medical information and inspection of the effectiveness
神田将哉1)2), 合田光寛1)2), 吉岡俊彦1)2), 吉田愛美1), 新村貴博2), 相澤風花2), 八木健太3), 濱野裕章3), 中馬真幸4), 岡田直人2), 石澤有紀5), 座間味義人1)6), 石澤啓介1)2)
Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 59-59, 2021.

	YIA-01. The electric pharmacologic effect evaluation in the isoflurane anesthesia dog of TASK-1 inhibitor doxapram: Examination of the possibility as the antiatrial fibrillation medicine 神林隆一1), 後藤愛1), 中瀬古(泉)寛子1), 武井義則1), 松本明郎2), 川合眞一3), 杉山篤1)2)3) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 60-60, 2021.

	YIA-02. Myocardium remodeling of the NRSF-GNAO1-CaMKII transcription control circuit, significance in the Ca2+ constancy 稲住英明1), 桑原宏一郎2), 中川靖章1), 冨田拓郎3), 中田勉3), 呉林なごみ4), 大矢未来2), 木下秀之1), 森内健史1), 柳澤洋1), 錦見俊雄1), 山田充彦3), 中尾一和5), 木村剛1) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 61-61, 2021.

YIA-02. Myocardium remodeling of the NRSF-GNAO1-CaMKII transcription control circuit, significance in the Ca2+ constancy
稲住英明1), 桑原宏一郎2), 中川靖章1), 冨田拓郎3), 中田勉3), 呉林なごみ4), 大矢未来2), 木下秀之1), 森内健史1), 柳澤洋1), 錦見俊雄1), 山田充彦3), 中尾一和5), 木村剛1)
Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 61-61, 2021.

	YIA-03. Examination of the meeting lymphatic vessel contractile function in the hypertensive condition of a patient 向田昌司1), 松井利康2), 水野理介1), 尾崎博1) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 62-62, 2021.

	YIA-04. Elucidation of the novel internalization mechanism of GPCR through the cysteine ornamentation 西山和宏1), 西村明幸2), 下田翔2), 加藤百合1), 西田基宏1)2) Annual Meeting of Japanese Association of Cardiovascular Pharmacology 31: 63-63, 2021.

ID
Password